arrow
C

Chih-ho Hong

University of British Columbia
H指数:11
被引数:657

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Lebrikizumab Provides Stable and Deep Long-Term Response with No/Minimal Fluctuations up to 3 Years in Patients with Moderate-to-Severe Atopic Dermatitis

Lebrikizumab在3年内为中度至重度特应性皮炎患者提供稳定且深度长效应答,且无/极少波动

2026-10-210
OAAI
Real-World Evidence of Upadacitinib in Atopic Dermatitis after Inadequate Response or Intolerance to Dupilumab: The CAN UpTIMISE Study

奥马帕尼布在特应性皮炎中的应用:在双卢木单抗治疗反应不佳或耐受性差后的真实世界证据:CAN UpTIMISE研究

2026-09-110
OAAI
Ruxolitinib cream in adults with moderate atopic dermatitis after failure of other topicals: A randomized trial

鲁索利替尼乳膏用于中度特应性皮炎成人患者(其他外用药物失败后):一项随机试验

2026-07-290
OAAI
P149 Efficacy of lebrikizumab at 16 weeks: pooled analyses from the ADvocate1 and ADvocate2 phase III trials in adolescent and older adult patients with moderate-to-severe atopic dermatitis

P149 青少年和成年中重度特应性皮炎患者中lebrikizumab 16周疗效:ADvocate1和ADvocate2 III期试验的合并分析

2026-06-260
OAAI
Long-Term Safety and Efficacy of Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis Treated for up to 6 Years: Final Results from the Open-Label Extension Trial ECZTEND

特应性皮炎中度至重度患者接受特立珠单抗治疗长达6年的长期安全性与有效性:开放标签扩展试验ECZTEND的最终结果

2026-02-050
OAAI
Long-term treatment of atopic dermatitis with roflumilast cream 0.15% in patients aged 6 years or older (INTEGUMENT-OLE clinical study): a plain language summary

使用0.15%罗氟司特乳膏长期治疗≥6岁特应性皮炎患者(INTEGUMENT-OLE临床研究):一份通俗语言摘要

2026-01-010
PRE
Efficacy of up to 4 years of tralokinumab in adults with moderate-to-severe atopic dermatitis

中重度特应性皮炎成人患者中曲尼司特长达4年的疗效

2025-11-011
OAAI
Raising the bar of efficacy in atopic dermatitis: lebrikizumab provides deep clinical and itch responses up to 16 weeks (ADvantage study)

提高特应性皮炎疗效标准:lebrikizumab可提供长达16周(ADvantage研究)的深度临床和瘙痒反应

2025-07-010
OAAI